Scholarlink

<p>Head and neck squamous cell carcinomas (HNSCCs) rank seventh among the most prevalent malignancies globally. The immune response in cancer conditions governs the course of the disease and clinical outlook. Interferons (IFNs) are a key part of the innate immune system and are essential in modulating the tumor microenvironment (TME). Additionally, IFNs could influence proliferation and affect differentiation, emigration, and death of cancer cells. The cGAS–stimulator of interferon genes (STING) signaling identifies cytosolic DNA and triggers an immune response. Aberrant induction of the cGAS–STING signaling may lead to excess and sustained release of type-I IFN, leading to imbalanced aggregation in various tissues or organs. It is noteworthy that STING signaling has shown a dual role, both promoting tumor resistance and antitumor immunity. Moreover, STING agonists have been investigated in recent studies; however, challenges such as toxicity should be addressed. IFNs have also been used as monotherapy or adjuvant treatment before chemotherapy to increase efficacy against HNSCC tumors. The present review briefly describes IFN signaling with a focus on the STING pathway, and discusses its role in modulating immunotherapy and chemotherapy effects in HNSCC.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Interferon signaling and STING pathway in head and neck cancers: unlocking immune secrets and therapeutic frontiers

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年10月3日

查看全文
  • Kosar Zolfaghari,
  • Mohammad Yazdi,
  • Shaghayegh Mohammadioun,
  • Fatemeh Tajafrooz,
  • Hesam Malekfarnood,
  • Kiarash Saleki,
  • Nima Rezaei

摘要

Head and neck squamous cell carcinomas (HNSCCs) rank seventh among the most prevalent malignancies globally. The immune response in cancer conditions governs the course of the disease and clinical outlook. Interferons (IFNs) are a key part of the innate immune system and are essential in modulating the tumor microenvironment (TME). Additionally, IFNs could influence proliferation and affect differentiation, emigration, and death of cancer cells. The cGAS–stimulator of interferon genes (STING) signaling identifies cytosolic DNA and triggers an immune response. Aberrant induction of the cGAS–STING signaling may lead to excess and sustained release of type-I IFN, leading to imbalanced aggregation in various tissues or organs. It is noteworthy that STING signaling has shown a dual role, both promoting tumor resistance and antitumor immunity. Moreover, STING agonists have been investigated in recent studies; however, challenges such as toxicity should be addressed. IFNs have also been used as monotherapy or adjuvant treatment before chemotherapy to increase efficacy against HNSCC tumors. The present review briefly describes IFN signaling with a focus on the STING pathway, and discusses its role in modulating immunotherapy and chemotherapy effects in HNSCC.